Antibiotics: pharma's Cinderella story

Finally, can the agents which promise rapid infection resolution and the potential of patient management outside the hospital setting create compelling pharmacoeconomic arguments to justify premium pricing?

Questions raised about affordability of asthma antibodies

GSK meanwhile says it is confident that pharmacoeconomic studies will prove the worth of biologics in reducing hospitalisations and the significant morbidity associated with oral steroid use.

Genzyme continues MS drug rollout across EU

The launch of Lemtrada follows a recommendation in July this year from the National Centre for Pharmacoeconomics (NCPE), which provides guidance on what drugs should be reimbursed on Ireland's healthcare

Taking contract research’s pulse

They are also seeing increased demand for pharmacoeconomic end points in trials and comparative effectiveness research (CER) to help meet payers' increasing demands on patient outcomes.

All eyes on pharma in Brazil

The Government will pay for specialised, new and expensive drugs but companies have to submit an HTA dossier complete with pharmacoeconomic analyses similar to those required by NICE.

Drug safety

Healthcare systems

Drug pricing

Digital

Finance and investment

Webinar: Maintaining market access through a pandemic, 6 months on

Sue Caleo-Naeyaert: Former Global Head Government Affairs, Policy and Pharmacoeconomics at Fresenius Kabi SwissBioSim.

WHITE PAPER: Patient nonadherence – the $637bn paradox

compliance with interventions supported by electronic monitoring devices. Pharmacoeconomics 2007; 25(8):621–635.

Plugging knowledge gaps to demonstrate the benefits of new medicines

Hayward Medical Communications recently presented a poster, titled The use of consensus techniques to inform health technology appraisals, at the 19th Annual European Conference of the International Society for Pharmacoeconomics and